HSP90B2P and neoplasm: Although some activation of these HSPs is also observed in Ganetespib-sensitive controls (Fig. 2a–c), it is significantly stronger in the resistant tumors, suggesting an HSP transcriptome rewiring that is actively selected for in the resistant tumor cells.